The Cancer Letter

Inside information on cancer research and drug development

In Brief

CPRIT gives $52M in grants to advance cancer research in Texas

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The governing body of the Cancer Prevention and Research Institute of Texas approved $51.8 million in grants to advance the state’s fight against cancer. The grants are a mix of academic research recruitment grants and product development research projects.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Funding Opportunities

DoD Ovarian Research Program FY25 anticipated funding opportunities

The FY25 Defense Appropriations Act is anticipated to provide funding for the Ovarian Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members and all women impacted by this disease. The Congressionally Directed Medical Research Programs, or CDMRP, at the U.S. Army Medical Research and Development Command is the program office managing these anticipated FY25 funding opportunities.
In Brief

Wistar’s Nan Zhang and Noam Auslander receive $1.2M in biomedical research grants from V Foundation

Nan ZhangNoam AuslanderNan Zhang and Noam Auslander, the Wistar Institute assistant professors, have both received independent funding totaling $1.2 million over the next three years for cancer research projects from the V Foundation for Cancer Research. The grants are awarded to cancer researchers deemed “V Scholars” and allow Zhang and Auslander to pursue separate projects aimed at new strategies to improve the effectiveness of certain cancer therapies.
Clinical Roundup

Monoclonal antibody improves survival in cancer-associated hyper-inflammatory disorder

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account